190 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
a draft label describing chronic and acute symptomatic benefit, in addition to acute reduction in ocular redness of reproxalap. The review period
8-K/A
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
filtration rate ("eGFR") total and chronic slope versus
irbesartan, narrowly missing statistical significance in eGFR total slope while achieving … statistical significance in eGFR chronic slope for purposes of regulatory review in the EU. All topline efficacy endpoints favored FILSPARI and patients
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
8 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
4:08pm
filtration rate ("eGFR") total and chronic slope versus
irbesartan, narrowly missing statistical significance in eGFR total slope while achieving … statistical significance in eGFR chronic slope for purposes of regulatory review in the EU. All topline efficacy endpoints favored FILSPARI and patients
8-K
EX-99.1
uyahzh229 h47uw
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
vrxiprcv523 9n9o
8 Aug 22
Ligand Reports Second Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
jaj84pfr2iy5va3yk6
17 Feb 22
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
4:03pm
8-K
EX-99.1
38hbhe rl8
3 Feb 21
Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
7:45am
8-K
EX-99.1
b8xpfni7
20 Oct 20
Results of Operations and Financial Condition
10:52am
8-K
EX-99.1
op9s7k6c7b 28csgnz
6 Feb 20
Ligand Reports Fourth Quarter and Full Year 2019 Financial Results
4:05pm
8-K
EX-99.1
qjb15wm5fsg9s ekq
5 Nov 19
Ligand Reports Third Quarter 2019 Financial Results
4:05pm